Parallel Advisors’s Pliant Therapeutics PLRX Stock Holding History

Parallel Advisors’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-658	Closed	-$5K	–	3272
2022 Q1	$5K	Sell	658 -75	-10%	-$765	﹤0.01%	2313
2021 Q4	$10K	Sell	733 -170	-19%	-$2.7K	﹤0.01%	2115
2021 Q3	$15K	Buy	903 +245	+37%	+$5.2K	﹤0.01%	1884
2021 Q2	$19K	Buy	+658	New	+$20.5K	﹤0.01%	1718
2020 Q4	–	Sell	-658	Closed	-$15K	–	2687
2020 Q3	$15K	Hold	658	–	–	﹤0.01%	1567
2020 Q2	$21K	Buy	+658	New	+$17.5K	﹤0.01%	1398

Other funds holding PLRX

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Parallel Advisors's PLRX Position: Q2 2022 in Review

Parallel Advisors sold out of Pliant Therapeutics (PLRX) in Q2 2022, closing a stake of 658 shares — an estimated $5K sold.

Parallel Advisors first reported a position in PLRX in Q2 2020 and held it in 6 quarters. The position peaked at $21K in Q2 2020. 88 funds tracked by Wall St. Rank hold PLRX as of Q2 2022.

Parallel Advisors reported no remaining Pliant Therapeutics position as of Q2 2022 after selling out during the quarter.
Parallel Advisors sold 658 Pliant Therapeutics shares in Q2 2022, an estimated $5K.
Parallel Advisors first reported a position in Pliant Therapeutics in Q2 2020 and held it in 6 quarters.
Parallel Advisors's Pliant Therapeutics position peaked at $21K in Q2 2020.
88 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2022.

Based on Parallel Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.